Literature DB >> 28125174

Pharmacologic Treatments for Binge-Eating Disorder.

Susan L McElroy1,2.   

Abstract

Binge-eating disorder (BED) is the most common eating disorder and is associated with poor physical and mental health outcomes. Psychological and behavioral interventions have been a mainstay of treatment for BED, but as understanding of this disorder has grown, pharmacologic agents have become promising treatment options for some patients. At this time, only one drug-the stimulant prodrug lisdexamfetamine-is approved for the treatment of BED. Numerous classes of medications including antidepressants, anticonvulsants, and antiobesity drugs have been explored as off-label treatments for BED with variable success. Although not all patients with BED may be suitable candidates for pharmacotherapy, all patients should be considered for and educated about pharmacologic treatment options. © Copyright 2017 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28125174     DOI: 10.4088/JCP.sh16003su1c.03

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

Review 1.  Lisdexamfetamine: A Review in Binge Eating Disorder.

Authors:  Young-A Heo; Sean T Duggan
Journal:  CNS Drugs       Date:  2017-11       Impact factor: 5.749

2.  Comparing men and women with binge-eating disorder and co-morbid obesity.

Authors:  Janet A Lydecker; Carlos M Grilo
Journal:  Int J Eat Disord       Date:  2018-03-01       Impact factor: 4.861

3.  Randomized controlled trial testing the effectiveness of adaptive "SMART" stepped-care treatment for adults with binge-eating disorder comorbid with obesity.

Authors:  Carlos M Grilo; Marney A White; Robin M Masheb; Valentina Ivezaj; Peter T Morgan; Ralitza Gueorguieva
Journal:  Am Psychol       Date:  2020 Feb-Mar

4.  Examining race as a predictor and moderator of treatment outcomes for binge-eating disorder: Analysis of aggregated randomized controlled trials.

Authors:  Janet A Lydecker; Ralitza Gueorguieva; Robin Masheb; Marney A White; Carlos M Grilo
Journal:  J Consult Clin Psychol       Date:  2019-04-22

Review 5.  [Eating and feeding disorders : New developments].

Authors:  Manfred M Fichter; Norbert Quadflieg
Journal:  Nervenarzt       Date:  2021-10-07       Impact factor: 1.214

6.  Randomized Controlled Trial of Behavioral Weight Loss and Stepped Care for Binge-Eating Disorder: 12-Month Follow-up.

Authors:  Carlos M Grilo; Marney A White; Valentina Ivezaj; Ralitza Gueorguieva
Journal:  Obesity (Silver Spring)       Date:  2020-09-27       Impact factor: 5.002

7.  Examining sex as a predictor and moderator of treatment outcomes for binge-eating disorder: Analysis of aggregated randomized controlled trials.

Authors:  Janet A Lydecker; Ralitza Gueorguieva; Robin Masheb; Marney A White; Carlos M Grilo
Journal:  Int J Eat Disord       Date:  2019-09-09       Impact factor: 4.861

8.  Testing the validity and clinical utility of the severity specifiers for binge-eating disorder for predicting treatment outcomes.

Authors:  Janet A Lydecker; Valentina Ivezaj; Carlos M Grilo
Journal:  J Consult Clin Psychol       Date:  2020-02

9.  Psychiatric comorbidity as predictor and moderator of binge-eating disorder treatment outcomes: an analysis of aggregated randomized controlled trials.

Authors:  Janet A Lydecker; Carlos M Grilo
Journal:  Psychol Med       Date:  2021-04-14       Impact factor: 10.592

10.  Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.

Authors:  Carlos M Grilo; Janet A Lydecker; Peter T Morgan; Ralitza Gueorguieva
Journal:  Clin Ther       Date:  2020-11-18       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.